How should we define and classify exacerbations in chronic obstructive pulmonary disease?

References

• Grupo de Trabajo de GesEPOC. [Spanish guidelines for COPD (GesEPOC)]. Arch. Bronconeumol. 48(Suppl. 1), 2–58 (2012).
   Google Scholar
• Miravitlles M, Ferrer M, Pont A et al.; IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59(5), 387–395 (2004).
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients’ health status following early identification of a COPD exacerbation. Eur. Respir. J. 30(5), 907–913 (2007).
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847–852 (2002).
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60(11), 925–931 (2005).
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A et al.;. Suceptibility of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363(12), 1128–1138 (2010).
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 11, 122 (2010).
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 21(1), 68–73 (2003).
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donalson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157(5 Pt 1), 1418–1422 (1998).
   PubMed Web of Science ®Google Scholar
• Donalson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171(5), 446–452 (2005).
   Google Scholar
• Kanner RE, Anthonisen NR, Connet JE.; Lower respiratory illnesses promote FEV1 decline in current smokers but no exsmokers with mild chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 164(3), 358–364 (2001).
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function changes in COPD exacerbation. Thorax 55(2), 114–120 (2000).
   Google Scholar
• Peces-Barba G, Barberà JA, Agustí A et al. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch. Bronconeumol. 44(5), 271–281 (2008).
   Google Scholar
• Hurst JR, Donaldson GC, Perera WR et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174(8), 867–874 (2006).
   PubMed Web of Science ®Google Scholar
• Perera WR, Hurst JR, Wilkinson TM et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 29(3), 527–534 (2007).
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez García MA, Catalán Serra P. The frequent exacerbator. A new phenotype in COPD? Hot Topics Respir. Med. 6, 7–12 (2011).
   Google Scholar
• Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiologic changes during sympton recovery from moderate exacerbations of COPD. Eur. Respir. J. 26(3), 420–428 (2005).
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin. Pulm. Med. 9, 191–197 (2002).
   Google Scholar
• Papi A, Belletato CM, Braccioni F et al. Infection of airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173(10), 1114–1121 (2006).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monsó E, Mensa J et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch. Bronconeumol. 44(2), 100–108 (2008).
   PubMedGoogle Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106(2), 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum colour to nature and outpatients management of acute exacerbations of COPD. Chest 117(6), 1638–1645 (2000).
   PubMed Web of Science ®Google Scholar
• Adams R, Chavannes N, Jones K, Ostergaard MS, Price D. Exacerbation of chronic obstructive pulmonary disease – a patients’ perspective. Prim. Care Respir. J. 15(2), 102–109 (2006).
   Google Scholar
• Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and stating of COPD and exacerbations. Semin. Respir. Crit. Care Med. 31(3), 267–275 (2010).
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther. Adv. Respir. Dis. 1(1), 61–76 (2007).
   PubMedGoogle Scholar